University of Tasmania
Browse

File(s) under permanent embargo

Diabetes therapies for dementia

journal contribution
posted on 2023-05-20, 05:50 authored by Moran, C, Michele CallisayaMichele Callisaya, Srikanth, V, Arvanitakis, Z
Purpose of Review: Type 2 diabetes (T2D) is a well-established risk factor for the development of dementia. Dementia and T2D share some underlying pathophysiology that has led to interest in the potential to repurpose drugs used in the management of T2D to benefit brain health. This review describes the scientific data available on the use of T2D medications for the risk reduction or management of dementia, in people with and without T2D.

Recent Findings: Results from basic laboratory research support the potential for commonly-used medications for T2D, including those with direct glucose-lowering properties, to have a beneficial effect on brain health. However, human studies have been mostly observational in nature and report conflicting results. Preliminary data suggest that intranasal insulin, metformin, and GLP-1 agonists show promise for dementia, but confirmatory evidence for their benefit in dementia is still lacking.

Summary: Current evidence does not support the repurposing of T2D medications for dementia risk reduction or management. Research in the field of T2D and dementia is active, and further data are required before definitive conclusions can be drawn.

History

Publication title

Current Neurology and Neuroscience Reports

Volume

19

Issue

8

Article number

58

Number

58

Pagination

1-9

ISSN

1528-4042

Department/School

Menzies Institute for Medical Research

Publisher

Springer Healthcare

Place of publication

United States

Rights statement

Copyright 2019 Springer Science-Business Media, LLC, part of Springer Nature

Repository Status

  • Restricted

Socio-economic Objectives

Clinical health not elsewhere classified

Usage metrics

    University Of Tasmania

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC